Literature DB >> 21521343

The association of serum prolactin concentration with inflammatory biomarkers - cross-sectional findings from the population-based Study of Health in Pomerania.

Nele Friedrich1, Harald J Schneider, Christin Spielhagen, Marcello Ricardo Paulista Markus, Robin Haring, Hans J Grabe, Michael Buchfelder, Henri Wallaschofski, Matthias Nauck.   

Abstract

OBJECTIVE: Prolactin (PRL) is involved in immune regulation and may contribute to an atherogenic phenotype. Previous results on the association of PRL with inflammatory biomarkers have been conflicting and limited by small patient studies. Therefore, we used data from a large population-based sample to assess the cross-sectional associations between serum PRL concentration and high-sensitivity C-reactive protein (hsCRP), fibrinogen, interleukin-6 (IL-6), and white blood cell (WBC) count. DESIGN AND POPULATION: From the population-based Study of Health in Pomerania (SHIP), a total of 3744 subjects were available for the present analyses. METHODS AND MEASUREMENTS: PRL and inflammatory biomarkers were measured. Linear and logistic regression models adjusted for age, sex, body-mass-index, total cholesterol and glucose were analysed.
RESULTS: Multivariable linear regression models revealed a positive association of PRL with WBC. Multivariable logistic regression analyses showed a significant association of PRL with increased IL-6 in non-smokers [highest vs lowest quintile: odds ratio 1·69 (95% confidence interval 1·10-2·58), P = 0·02] and smokers [OR 2·06 (95%-CI 1·10-3·89), P = 0·02]. Similar results were found for WBC in non-smokers [highest vs lowest quintile: OR 2·09 (95%-CI 1·21-3·61), P = 0·01)] but not in smokers. Linear and logistic regression analyses revealed no significant associations of PRL with hsCRP or fibrinogen.
CONCLUSIONS: Serum PRL concentrations are associated with inflammatory biomarkers including IL-6 and WBC, but not hsCRP or fibrinogen. The suggested role of PRL in inflammation needs further investigation in future prospective studies.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21521343     DOI: 10.1111/j.1365-2265.2011.04075.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  8 in total

1.  Prolactin concentrations in newly diagnosed, antipsychotic-naïve patients with nonaffective psychosis.

Authors:  Clemente Garcia-Rizo; Emilio Fernandez-Egea; Cristina Oliveira; Azucena Justicia; Eduard Parellada; Miguel Bernardo; Brian Kirkpatrick
Journal:  Schizophr Res       Date:  2011-08-09       Impact factor: 4.939

2.  Prolactin as a predictor of endothelial dysfunction and arterial stiffness progression in menopause.

Authors:  G Georgiopoulos; I Lambrinoudaki; F Athanasouli; E Armeni; A Koliviras; A Augoulea; D Rizos; C Papamichael; A Protogerou; K Stellos; K Stamatelopoulos
Journal:  J Hum Hypertens       Date:  2017-03-23       Impact factor: 3.012

Review 3.  Current Understanding and Management of Plasma Cell Mastitis: Can We Benefit from What We Know?

Authors:  Mengying Xing; Shichang Zhang; Xiaoming Zha; Jiexin Zhang
Journal:  Breast Care (Basel)       Date:  2021-10-06       Impact factor: 2.268

Review 4.  The Obesity-Impulsivity Axis: Potential Metabolic Interventions in Chronic Psychiatric Patients.

Authors:  Adonis Sfera; Carolina Osorio; Luzmin Acosta Inderias; Victoria Parker; Amy I Price; Michael Cummings
Journal:  Front Psychiatry       Date:  2017-02-13       Impact factor: 4.157

5.  Cross-sectional association between prolactin levels and non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus: a retrospective analysis of patients from a single hospital in China.

Authors:  Yuanyuan Zhang; Huaizhen Liu
Journal:  BMJ Open       Date:  2022-10-03       Impact factor: 3.006

6.  Serum prolactin concentrations as risk factor of metabolic syndrome or type 2 diabetes?

Authors:  Lisa Balbach; Henri Wallaschofski; Henry Völzke; Matthias Nauck; Marcus Dörr; Robin Haring
Journal:  BMC Endocr Disord       Date:  2013-03-21       Impact factor: 2.763

7.  Cohort profile: Greifswald approach to individualized medicine (GANI_MED).

Authors:  Hans J Grabe; Heinrich Assel; Thomas Bahls; Marcus Dörr; Karlhans Endlich; Nicole Endlich; Pia Erdmann; Ralf Ewert; Stephan B Felix; Beate Fiene; Tobias Fischer; Steffen Flessa; Nele Friedrich; Mariacarla Gadebusch-Bondio; Manuela Gesell Salazar; Elke Hammer; Robin Haring; Christoph Havemann; Michael Hecker; Wolfgang Hoffmann; Birte Holtfreter; Tim Kacprowski; Kathleen Klein; Thomas Kocher; Holger Kock; Janina Krafczyk; Jana Kuhn; Martin Langanke; Uwe Lendeckel; Markus M Lerch; Wolfgang Lieb; Roberto Lorbeer; Julia Mayerle; Konrad Meissner; Henriette Meyer zu Schwabedissen; Matthias Nauck; Konrad Ott; Wolfgang Rathmann; Rainer Rettig; Claudia Richardt; Karen Saljé; Ulf Schminke; Andrea Schulz; Matthias Schwab; Werner Siegmund; Sylvia Stracke; Karsten Suhre; Marius Ueffing; Saskia Ungerer; Uwe Völker; Henry Völzke; Henri Wallaschofski; Vivian Werner; Marek T Zygmunt; Heyo K Kroemer
Journal:  J Transl Med       Date:  2014-05-23       Impact factor: 5.531

Review 8.  Dopamine-prolactin pathway potentially contributes to the schizophrenia and type 2 diabetes comorbidity.

Authors:  C Gragnoli; G M Reeves; J Reazer; T T Postolache
Journal:  Transl Psychiatry       Date:  2016-04-19       Impact factor: 6.222

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.